[go: up one dir, main page]

MX2009006564A - Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico. - Google Patents

Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico.

Info

Publication number
MX2009006564A
MX2009006564A MX2009006564A MX2009006564A MX2009006564A MX 2009006564 A MX2009006564 A MX 2009006564A MX 2009006564 A MX2009006564 A MX 2009006564A MX 2009006564 A MX2009006564 A MX 2009006564A MX 2009006564 A MX2009006564 A MX 2009006564A
Authority
MX
Mexico
Prior art keywords
modified
glucagon
buffers
physiological
seq
Prior art date
Application number
MX2009006564A
Other languages
English (en)
Inventor
Richard D Dimarchi
Maria Dimarchi
Joseph Chabenne
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of MX2009006564A publication Critical patent/MX2009006564A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen péptidos de glucagán modificados que tienen solubilidad mejorada al mantener la actividad del agonista de glucagán. Los péptidos de glicógeno han sido modificados mediante la sustitución de aminoácidos de origen natural con y/o adición de aminoácidos cargados a la terminal carboxi del péptido. Los agonistas de glucagón modificados pueden modificarse aún más mediante pegilación o mediante la adición de un péptido carboxi terminal seleccionado del grupo que comprende SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23 o ambos, para potenciar aún más la solubilidad de los análogos del agonista de glucagón.
MX2009006564A 2007-01-05 2008-01-03 Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico. MX2009006564A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87891907P 2007-01-05 2007-01-05
PCT/US2008/050099 WO2008086086A2 (en) 2007-01-05 2008-01-03 Glucagon analogs exhibiting enhanced solubility in physiological ph buffers

Publications (1)

Publication Number Publication Date
MX2009006564A true MX2009006564A (es) 2009-06-26

Family

ID=39609306

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006564A MX2009006564A (es) 2007-01-05 2008-01-03 Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico.

Country Status (12)

Country Link
US (1) US8669228B2 (es)
EP (1) EP2124974B1 (es)
JP (1) JP5890085B2 (es)
CN (1) CN101578102B (es)
AU (1) AU2008205229B2 (es)
CA (1) CA2674354A1 (es)
ES (1) ES2628063T3 (es)
IL (1) IL199263A (es)
MX (1) MX2009006564A (es)
RU (1) RU2477286C2 (es)
SG (1) SG177953A1 (es)
WO (1) WO2008086086A2 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572952T3 (es) * 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
MX2009008241A (es) * 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
US8980830B2 (en) * 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
CA2713348C (en) * 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010011439A2 (en) 2008-06-17 2010-01-28 Indiana University Research And Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
WO2009155257A1 (en) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
AU2011231503C1 (en) 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
CN102933598A (zh) * 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
EP2635296B1 (en) 2010-11-03 2014-12-24 Arecor Limited Novel composition comprising glucagon
PE20140186A1 (es) 2010-12-22 2014-02-13 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2830974A1 (en) 2011-03-28 2012-10-04 Jesper F. Lau Novel glucagon analogues
CN102212127B (zh) * 2011-05-17 2015-02-04 上海景泽生物技术有限公司 胰高血糖素样肽-2聚乙二醇结合物及其制备方法和用途
CN103649115B (zh) * 2011-06-10 2016-01-20 诺沃—诺迪斯克有限公司 多肽
JP6179864B2 (ja) 2011-06-22 2017-08-16 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト
CN103748109A (zh) 2011-06-22 2014-04-23 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共同激动剂
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
TWI596110B (zh) 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
EP2780031B1 (en) 2011-11-17 2018-03-07 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
SG11201500375PA (en) 2012-07-23 2015-02-27 Zealand Pharma As Glucagon analogues
US9546205B2 (en) 2012-09-17 2017-01-17 Imperial Innovations Limited Peptide analogues of glucagon and GLP1
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CA2895875A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
PL2986313T3 (pl) 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
CN119119235A (zh) 2013-10-17 2024-12-13 西兰制药公司 酰化胰高血糖素类似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
AR098614A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Compuesto para el tratamiento de hipoglicemia severa
AR098615A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
AR098616A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
JP2017509603A (ja) 2014-02-18 2017-04-06 ノヴォ ノルディスク アー／エス 安定なグルカゴン類似体及び低血糖症の処置のための使用
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3206710B1 (en) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA55068A (fr) 2014-10-24 2022-01-05 Merck Sharp & Dohme Co-agonistes des récepteurs du glucagon et du glp-1
AU2015340586B2 (en) 2014-10-29 2020-04-30 Zealand Pharma A/S GIP agonist compounds and methods
CN107636009B (zh) * 2014-12-30 2021-04-16 韩美药品株式会社 具有改善的稳定性的胰高血糖素衍生物
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TWI713541B (zh) 2015-06-30 2020-12-21 南韓商韓美藥品股份有限公司 升糖素衍生物及包含該衍生物之長效接合物之組成物
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
HUE059737T2 (hu) 2015-12-31 2022-12-28 Hanmi Pharm Ind Co Ltd Glükagon, GLP-1 és GIP receptor aktiváló tripla aktivátor
WO2017200944A1 (en) * 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN105968186B (zh) * 2016-06-02 2020-10-30 中国药科大学 具有长效化作用的胰高血糖素(Glu)类似物及其应用
EP3468569A4 (en) * 2016-06-09 2020-05-27 AmideBio LLC GLUCAGON ANALOGS AND METHODS OF USING THE SAME
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
PE20190355A1 (es) 2016-06-29 2019-03-07 Hanmi Pharm Ind Co Ltd Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
CA3067674A1 (en) * 2017-06-29 2019-01-03 Ureka Sarl Pro-drug peptide with improved pharmaceutical properties
WO2020163125A1 (en) 2019-02-05 2020-08-13 Eli Lilly And Company Glucagon analog agonists and methods of using the same
EP4329812A1 (en) 2021-04-27 2024-03-06 Aardvark Therapeutics Inc. Combination of bitter receptor agonist and gut-signaling compound
GB202109087D0 (en) 2021-06-24 2021-08-11 Norwegian Univ Sci & Tech Ntnu Therapeutic methods and devices
CN119930789A (zh) * 2023-11-06 2025-05-06 成都奥达生物科技有限公司 一种gcg激动剂化合物

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275152A (en) * 1977-02-03 1981-06-23 Eastman Kodak Company Hydrolysis of protein-bound cholesterol esters
PT83613B (en) 1985-10-28 1988-11-21 Lilly Co Eli Process for the selective chemical removal of a protein amino-terminal residue
US5539084A (en) * 1989-02-17 1996-07-23 Coselco Mimotopes Pty. Ltd. Method for the use and synthesis of peptides
CA2024855C (en) 1990-09-07 1997-12-09 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Process and intermediates for producing glucagon
JPH04145099A (ja) 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途
US5510459A (en) * 1991-01-17 1996-04-23 Zymogenetics, Inc. Glucagon antagonists
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5480867A (en) * 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
WO1997029180A1 (en) 1996-02-06 1997-08-14 Eli Lilly And Company Diabetes therapy
WO1998011126A1 (en) 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998024464A1 (en) 1996-12-03 1998-06-11 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
EP1119625B1 (en) 1998-10-07 2005-06-29 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
DE69938669D1 (de) * 1998-12-07 2008-06-19 Sod Conseils Rech Applic Analoge des glucagon ähnlichen peptides-1 (glp-1)
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
DE60012721T4 (de) 1999-03-29 2010-09-09 Uutech Ltd., Coleraine Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
AU2001257278A1 (en) 2000-04-27 2001-11-07 Bionebraska, Inc. Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
US6677136B2 (en) * 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
CA2410604A1 (en) * 2000-06-14 2001-12-20 Cytovax Biotechnologies, Inc. Use of coiled-coil structural scaffold to generate structure-specific peptides
KR100847615B1 (ko) 2000-06-16 2008-07-21 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드-1 유사체
US20030204063A1 (en) * 2000-08-02 2003-10-30 Denis Gravel Modified biological peptides with increased potency
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US20020045572A1 (en) 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
ATE516820T1 (de) * 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
AU2002327430A1 (en) * 2001-08-08 2003-02-24 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
AR036711A1 (es) * 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7238670B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
MXPA04003569A (es) 2001-10-19 2004-07-23 Lilly Co Eli Mezclas bifasicas de glp-1 e insulina.
AU2002351752A1 (en) * 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
US20060252916A1 (en) * 2002-06-04 2006-11-09 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
WO2003103697A2 (en) 2002-06-11 2003-12-18 Cell Therapeutics Scandinavia Ab Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
CA2489323A1 (en) 2002-06-15 2003-12-24 Enteromed, Inc. Treatment of non-alcoholic fatty liver disease
EP1539210A4 (en) 2002-09-06 2006-06-07 Bayer Pharmaceuticals Corp GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE
US7192922B2 (en) * 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
JP2006520818A (ja) * 2003-03-19 2006-09-14 イーライ リリー アンド カンパニー ポリエチレングリコール結合ｇｌｐ−１化合物
CA2521784C (en) * 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
WO2004103390A2 (en) 2003-05-15 2004-12-02 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
JP2007524592A (ja) * 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
EP1633390B1 (en) 2003-06-03 2012-01-18 Novo Nordisk A/S Stabilized pharmaceutical glp-1 peptide compositions
UA87458C2 (ru) * 2003-06-12 2009-07-27 Елі Ліллі Енд Компані Гибридные белки-аналоги glp-1
US20050124550A1 (en) * 2003-06-18 2005-06-09 Peri Krishna G. Compounds that modulate the glucagon response and uses thereof
AU2004273573B2 (en) * 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
US7364875B2 (en) * 2003-10-30 2008-04-29 Cresent Innovations, Inc. Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
WO2005058954A1 (en) * 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 compounds
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
BRPI0606992A2 (pt) * 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
EP1863537A2 (en) * 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
WO2006121904A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
ATE482724T1 (de) 2005-05-13 2010-10-15 Lilly Co Eli Pegylierte glp-1-verbindungen
EP1891105B1 (en) 2005-06-13 2012-04-11 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
US20090286722A1 (en) 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
ES2572952T3 (es) * 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
AU2007221366B2 (en) 2006-02-22 2012-08-23 Msd Italia S.R.L. Oxyntomodulin derivatives
EP1996224B1 (en) * 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
CN104193815A (zh) * 2006-09-08 2014-12-10 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
MX2009008241A (es) * 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
US7859468B2 (en) * 2007-08-30 2010-12-28 Research In Motion Limited Mobile wireless communications device including a folded monopole multi-band antenna and related methods
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
EP2650006A1 (en) 2007-09-07 2013-10-16 Ipsen Pharma S.A.S. Analogues of exendin-4 and exendin-3
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
WO2009034117A1 (en) 2007-09-11 2009-03-19 Novo Nordisk A/S Mixture comprising an amylin peptide and a protracted insulin
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
HUE044174T2 (hu) 2008-02-01 2019-10-28 Ascendis Pharma As Önhasítható linkert tartalmazó elõvegyület
WO2009155257A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
WO2010011439A2 (en) 2008-06-17 2010-01-28 Indiana University Research And Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
AR072160A1 (es) * 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
AU2009327418A1 (en) * 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
KR20110114568A (ko) 2008-12-19 2011-10-19 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 디펩티드 링크된 약효 물질
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers

Also Published As

Publication number Publication date
JP2010515686A (ja) 2010-05-13
WO2008086086A2 (en) 2008-07-17
SG177953A1 (en) 2012-02-28
JP5890085B2 (ja) 2016-03-22
US8669228B2 (en) 2014-03-11
AU2008205229B2 (en) 2014-03-27
CN101578102A (zh) 2009-11-11
EP2124974A2 (en) 2009-12-02
RU2477286C2 (ru) 2013-03-10
US20100190699A1 (en) 2010-07-29
RU2009129961A (ru) 2011-02-10
AU2008205229A1 (en) 2008-07-17
IL199263A (en) 2013-09-30
EP2124974B1 (en) 2017-03-15
ES2628063T3 (es) 2017-08-01
EP2124974A4 (en) 2010-03-31
CN101578102B (zh) 2013-07-17
CA2674354A1 (en) 2008-07-17
WO2008086086A3 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
MX2009006564A (es) Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico.
MX2010012695A (es) Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
TN2009000313A1 (en) Glucagon/glp - 1 receptor co-agonists
EA019203B9 (ru) Коагонисты глюкагонового рецептора/glp-1-рецептора
NZ603811A (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
NZ590050A (en) Fgf21 mutants and uses thereof
NZ600732A (en) Oxyntomodulin peptide analogue
NZ603813A (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
NZ600731A (en) Oxyntomodulin peptide analogue
WO2007056362A3 (en) Glucagon analogs exhibiting physiological solubility and stability
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
NZ627111A (en) Variants of activin iib receptor polypeptides and uses thereof
NZ630484A (en) Compositions and methods for treatment of metabolic disorders and diseases
NZ704192A (en) Cell-penetrating peptides and uses therof
MX2010002001A (es) Peptido cdca1 y agente farmaceutico que comprende elmismo.
IN2014CN02050A (es)
MX350126B (es) Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.
NZ606584A (en) Binding proteins for hepcidin
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
MX2008009493A (es) Peptido novedoso y uso del mismo.
NZ600363A (en) Modified porcine somatotropin polypeptides and their uses
MX2019008056A (es) Agonistas del receptor pac1 (maxcaps) y usos de estos.
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
NZ614557A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
ZA200901342B (en) Cytokine derivatives

Legal Events

Date Code Title Description
FG Grant or registration